AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 171 min read$BEAM

Evans John M. sold $1.2M of BEAM

Evans John M. (CEO) sold 50,000 shares of Beam Therapeutics Inc. (BEAM) at an average of $23.77 ($23.57–$23.98, $1.19M total) across 2 trades over 2026-10-15 to 2026-10-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Evans John M.
Published Oct 17, 2026, 12:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 17, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BEAM
Bearish
high confidence
Mentioned
$BEAM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BEAMBearishLow
01

Why it matters

The disclosed sale reduces the CEO's ownership and may be interpreted by the market as a lack of confidence, prompting short‑term price weakness.

02

Market read

Primary insider sale news; modest materiality for traders monitoring biotech stocks and insider activity.

03

What to watch

Potential upcoming clinical data releases could offset the sell‑off if positive.

Relevance 5/10Novelty 6/10Timing: after-hours on filing day

Background

Form 4 filings provide transparent disclosure of insider transactions. BEAM is a CRISPR‑based gene‑editing company listed on NASDAQ.

Company-level read

Ticker impact

$BEAMBearishHigh confidence
Context

CEO Evans John M. sold 50,000 shares for $1.19M via a 10b5‑1 plan, reducing his stake to 1,047,205 shares.

Expected impact

likely downward pressure as the market prices the CEO's sell-off

Evidence & confidence

Form 4 filings are primary disclosures; a $1.2M sale by the CEO is material for a mid‑cap biotech and often triggers short‑term selling.

Market effects

Sector

May raise caution for biotech sector investors tracking insider activity.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact; relevant primarily to BEAM shareholders.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged 10b5‑1 plan and not reflect negative outlook.

Key entities

  • Company
    Beam Therapeutics Inc.

    NASDAQ‑listed biotech focused on gene editing.

  • Individual
    Evans John M.

    CEO of Beam Therapeutics, insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BEAM insider trading history →

Related articles

OCT 13
$BEAMMedAI 8/10

Beam Therapeutics reports early data on gene therapy for GSDIa

Beam Therapeutics (BEAM) reported early Phase 1/2 trial data for BEAM-301, a gene therapy for GSDIa, showing dose-dependent improvements in fasting hypoglycemia and reduced starch intake. The trial enrolled six patients, with median follow-up of 313 days for the 20 mg cohort and 53 days for the 40 mg cohort. All patients experienced adverse events, but no serious safety concerns were reported. The company will discuss the data at an investor event on October 27.

investing.com2 min